Is LNTH a buy according to AI stock analysis?

LNTH AI stock analysis rates Lantheus Holdings at 66 out of 100. The business is a cash-generative radiopharmaceutical franchise with a reported ~$7 billion takeover process from Curium that sits above the current price, but investment certainty is medium because PYLARIFY sales are declining, near-term revenue is guided down, and the deal could still fail to close. Any buy decision must account for personal risk tolerance and the event-driven nature of the stock.

What is the LNTH AI stock forecast?

The LNTH AI stock forecast uses scenario ranges around the July 31, 2026 close of $99.64 and the reported ~$7 billion Curium acquisition value of about $107.5 per share. The model projects a bullish range of $118 to $130 if the deal completes at or above the reported value, a base range of $100 to $112 if it completes near the reported value or tracks the $112.75 consensus target, and a bearish range of $75 to $90 if the deal falls through.

What technical levels matter for LNTH?

LNTH key technical levels as of the August 3, 2026 data cutoff include resistance near $100.84 to $103.06 and the $111.86 high, and support near $97.61 to $98.62, $96.40, and $87.18 (the 61.8% Fibonacci level). The stock is above the 200-day moving average near $78.54 but below the 50-day moving average near $103.53.

Can AI predict LNTH stock price?

No, AI cannot reliably predict stock prices. The LNTH AI stock analysis uses scenario ranges, fundamental data, and technical levels to frame possible outcomes. LNTH can move sharply on the Curium takeover outcome, FDA decisions on LNTH-2501 or PNT2003, PYLARIFY competitive data, Medicare reimbursement changes, and broader healthcare sector sentiment after any data cutoff.

How should I use this LNTH AI trading strategy?

This LNTH AI trading strategy is an analytical framework, not personalized advice. It describes an event-driven M&A spread approach, a trend-following setup, and a fundamental monitoring framework, each with specific risk controls. Every trader should adapt position sizing to their own risk tolerance, use stop losses, treat the pending deal as a binary event, and not rely on a single analysis for trading decisions.

Why did LNTH stock fall from its June high?

LNTH rose to a 52-week high of $111.86 on June 30, 2026, partly on takeover and PYLARIFY TruVu approval optimism, then pulled back about 11% to $99.64 by July 31, 2026. The pullback reflects profit taking after the strong run, the June 26, 2026 Complete Response Letter for LNTH-2501, a pause before the August 6, 2026 Q2 earnings report, and the market pricing in deal uncertainty as the reported Curium talks proceed.

Lantheus Holdings, Inc. research snapshot

LNTH AI Stock Analysis

LNTH AI stock analysis as of the August 3, 2026 data cutoff reads Lantheus Holdings as a leading radiopharmaceutical company whose shares are now driven primarily by an advanced takeover process. Bloomberg reported on July 28, 2026 that Curium, a private-equity backed radiopharma firm, is in advanced talks to acquire Lantheus in a deal valued at roughly $7 billion that could be announced in the coming days. That value implies about $107.5 per share against the $99.64 close of July 31, 2026, and a market capitalization near $6.49 billion. Underlying the deal, Lantheus reported Q1 2026 revenue of $377.3 million, PYLARIFY sales of $240.9 million (down 6.5% year over year), adjusted EPS of $1.46, and reaffirmed full-year 2026 guidance of $1.4 billion to $1.45 billion in revenue and $5.00 to $5.25 in adjusted EPS. The stock trades at about 23.9x trailing GAAP earnings with strong free cash flow, but near-term growth has stalled as PYLARIFY loses share ahead of the TruVu conversion, and the FDA issued a Complete Response Letter for LNTH-2501 on June 26, 2026. This page is informational research and not investment advice.

Current price

$99.64

Market cap

$6.49 billion

AI score

66 / 100

Rating

Solid but slowing radiopharmaceutical franchise in an active ~$7B takeover process, trading below the reported Curium deal value

Trend status

Above the 200-day moving average but below the 50-day, consolidating near $100 after a pullback from the June high near $111.86, with Curium acquisition talks in an advanced stage

Data cutoff (updated monthly)

August 4, 2026

Informational use only. This page is not investment advice.

Research quality check

information Richness: B-level information richness. Lantheus has regular SEC filings, a Q1 2026 earnings release and call, sell-side coverage, and active deal news flow. The August 3, 2026 refresh re-fetched current price, market cap, valuation ratios, Q1 2026 results, guidance, analyst targets, and the Curium acquisition reports from StockAnalysis.com, Barchart, the Q1 2026 press release, and press coverage.
bias Check: The main bias risk is anchoring to the takeover narrative. The analysis separates the reported ~$7 billion deal value from the standalone business outlook, and flags that PYLARIFY sales fell 6.5% in Q1 2026, FY2026 revenue is guided down year over year, and the LNTH-2501 Complete Response Letter adds regulatory uncertainty. The deal may also fail to close, which would leave the stock exposed to standalone valuation.
ai Confidence: High for the July 31, 2026 close of $99.64, market cap math, Q1 2026 reported results, guidance, balance sheet, and common valuation ratios that match across StockAnalysis.com, Barchart, and the company press release. Medium for forward outcomes because the takeover process, FDA actions, and PYLARIFY competitive dynamics can change the price faster than any static page.
investment Certainty: Medium. The franchise generates strong cash flow and the reported deal value sits above the current price, but investment certainty is lower than data confidence because a takeover can be withdrawn, PYLARIFY growth is negative, and FDA regulatory friction persists.

Quick verdict table

Dimension	Conclusion	Confidence
Business quality	Lantheus sells diagnostic radiopharmaceuticals and is building a therapeutic pipeline. PYLARIFY is the market-leading PSMA PET agent in prostate cancer, DEFINITY supports ultrasound cardiology, and Neuraceq and newer neurology assets add diversification. The business is cash generative but near-term revenue is roughly flat as PYLARIFY loses share.	Medium-high
Moat	The moat comes from FDA-approved radiopharmaceutical manufacturing, a first-mover position in PSMA PET imaging, distribution relationships, and the newly approved PYLARIFY TruVu formulation that improves supply flexibility. Competition from Telix and Novartis is intensifying, which is why PYLARIFY sales declined in Q1 2026.	Medium
Management	CEO Mary Anne Heino has repositioned the portfolio, divesting the SPECT business, securing PYLARIFY TruVu approval, and achieving tentative approval for PNT2003. Leadership turnover is a listed risk factor, and the Complete Response Letter for LNTH-2501 shows regulatory execution can slip.	Medium
Financial trend	Q1 2026 revenue rose 1.2% to $377.3 million, adjusted EPS fell 4.6% to $1.46, and PYLARIFY sales fell 6.5%. FY2026 guidance of $1.4 billion to $1.45 billion in revenue is below the $1.54 billion reported in 2025. Free cash flow remains strong at $377 million over trailing twelve months.	High
Valuation	At $99.64, LNTH trades at 23.9x trailing GAAP earnings, 18.6x forward earnings, 4.2x sales, and 17.2x free cash flow. The reported ~$7 billion Curium deal implies about $107.5 per share, roughly 8% above the current price.	Medium-high
Technical trend	The stock closed at $99.64 on July 31, 2026, above the 200-day moving average near $78.54 but below the 50-day moving average near $103.53, after peaking at $111.86 on June 30, 2026. RSI near 42 and Barchart turning points cluster between support near $96.40 and resistance near $103.06.	Medium
Risk level	Takeover deal failure risk, PYLARIFY share loss to Telix Illuccix and Novartis Pluvicto read-through, the LNTH-2501 Complete Response Letter, FDA timing for PNT2003, Medicare reimbursement for PSMA PET, and dependence on third-party manufacturing facilities.	High
AI confidence	High for reported financials and price data that cross-validated across StockAnalysis.com, Barchart, and the Q1 2026 press release. Medium for the forward view because the deal outcome and FDA timeline dominate the share price.	High data confidence
Investment certainty	Medium certainty. The reported deal value is above the market price, but the deal may not close, and standalone growth is currently negative, so conviction is limited for a static page.	Medium

LNTH AI stock forecast

LNTH AI Stock Forecast Scenarios

The LNTH AI stock forecast is framed around the reported ~$7 billion Curium acquisition process plus the standalone business outlook. At the July 31, 2026 close of $99.64, the reported deal value implies about $107.5 per share. A three-scenario model using FY2027 consensus adjusted EPS of $6.31 and target multiples of 20x, 17x, and 14x produced a bullish value near $126, a base near $107, and a bearish near $88, which aligns with the analyst range of $98 to $129 and the $112.75 consensus target. These scenario ranges are model outputs, not predictions.

Bullish case

$118 to $130

More likely if the Curium deal is announced and completes at or above the reported ~$7 billion value, a higher bid emerges, PYLARIFY TruVu stabilizes PSMA PET share, and PNT2003 reaches final FDA approval.

Base case

$100 to $112

More likely if the deal completes near the reported ~$7 billion value (about $107.5 per share), the stock converges toward the $112.75 consensus target, PYLARIFY holds share through the TruVu conversion, and full-year guidance is met.

Bearish case

$75 to $90

More likely if the deal falls through, PYLARIFY continues to lose share, LNTH-2501 approval is further delayed, FY2026 revenue comes in near the low end of guidance, and the stock reverts toward a standalone multiple.

LNTH AI technical analysis

LNTH AI Technical Analysis

LNTH AI technical analysis as of the August 3, 2026 data cutoff shows the stock closing at $99.64 on July 31, above the 200-day moving average near $78.54 but below the 50-day moving average near $103.53, after peaking at $111.86 on June 30, 2026. Barchart turning points cluster between support near $96.40 and resistance near $103.06, with the 61.8% Fibonacci retracement near $87.18. The 14-day RSI near 42 suggests neutral momentum after the pullback.

Level	Value	Why it matters
Current price	$99.64	Close on July 31, 2026 from StockAnalysis.com; after-hours quote was $98.00.
Resistance 1	$100.84 to $103.06	Barchart turning points, with the 50-day moving average near $103.53 at the top of the zone.
Resistance 2	$111.86	The 52-week and all-time high set on June 30, 2026. A break above would signal renewed strength.
Support 1	$97.61 to $98.62	Barchart first and second support levels below the current price.
Support 2	$96.40	Barchart third support level. A break below would test the July pullback structure.
Support 3	$87.18	The 61.8% Fibonacci retracement of the $47.25 to $111.86 range.
200-day moving average	~$78.54	Longer-term trend support. The stock is currently above this level.
50-day moving average	~$103.53	Short-term resistance that needs to be reclaimed for a renewed uptrend.
Momentum	RSI near 42.45	Neutral momentum after the pullback from the June high near $111.86.
Volume	~1.02 million shares	July 31, 2026 volume near the 20-day average of about 923,000 shares.
Volatility	IV near 28.3%, IV percentile ~2%	Implied volatility is low relative to its own history, reflecting the pending deal event.
Invalidation	Close below $87.18	A decisive close below the 61.8% Fibonacci level, or below the 200-day moving average near $78.54, would break the longer-term structure.

LNTH AI trading strategy

LNTH AI Trading Strategy Framework

The LNTH AI trading strategy is an analytical framework, not personalized advice. The stock is currently driven more by the reported Curium acquisition process than by quarterly fundamentals, so effective strategies monitor the deal status, FDA events, PYLARIFY volume, and technical levels, with risk controls sized for a potential gap in either direction.

Event-driven M&A spread framework

The reported ~$7 billion deal implies about $107.5 per share against the $99.64 close, leaving a roughly 8% spread that reflects deal risk and timing. A position built on this spread depends on the deal being announced and closing at the reported value, with the deal reportedly close to announcement as of July 28, 2026.

If the deal is withdrawn, the stock could gap down toward standalone value near the $87 to $90 zone or lower. Treat the spread as a binary event with a defined maximum loss and no averaging down on a failed deal.

Trend-following setup

Wait for LNTH to reclaim the 50-day moving average near $103.53 and break above the $103.06 to $106 resistance zone on rising volume, which would target the $111.86 high. This works best if the deal is confirmed or PYLARIFY TruVu momentum becomes visible.

A close back below the $96.40 support or a failed breakout would invalidate the setup. Size the position for the possibility of a large gap after any deal or FDA headline.

Fundamental monitoring framework

Track what matters most: the Curium deal announcement and terms, PYLARIFY and PYLARIFY TruVu sales volume, PNT2003 final FDA approval, the LNTH-2501 Complete Response Letter resolution, Medicare reimbursement for PSMA PET, and the Q2 2026 earnings call on August 6, 2026.

Reduce exposure when price moves are driven by takeover speculation without a confirmed transaction or matching clinical or regulatory evidence.

Investment research summary

Four-master Research Compression

Business essence

Lantheus makes diagnostic radiopharmaceuticals that help clinicians find and follow disease. PYLARIFY, the market-leading PSMA PET agent for prostate cancer, is the largest product, with DEFINITY in cardiology, Neuraceq and other neurology agents, and a therapeutic pipeline led by PNT2003. Customers pay for FDA-approved imaging products that change treatment decisions.

Moat

The moat rests on FDA-approved radiopharmaceutical manufacturing, a first-mover position in PSMA PET imaging, distribution relationships, and the newly approved PYLARIFY TruVu formulation that improves supply flexibility. Telix and Novartis are investing heavily in the same space, and PYLARIFY sales fell 6.5% in Q1 2026, showing the moat is under pressure.

Munger risk inversion

The thesis fails if the Curium deal collapses and the stock reverts to standalone value, PYLARIFY keeps losing share to Telix Illuccix and Novartis Pluvicto read-through, the LNTH-2501 Complete Response Letter is not resolved, PNT2003 is delayed, or Medicare reimbursement for PSMA PET is reduced.

Management

CEO Mary Anne Heino has executed a clear strategy: divest the SPECT business, win FDA approval for PYLARIFY TruVu, achieve tentative approval for PNT2003, and focus on PET radiodiagnostics. Leadership turnover is listed as a risk factor, and the LNTH-2501 Complete Response Letter shows third-party manufacturing dependencies can slip.

Industry trend

Radiopharmaceuticals and theranostics are a secular growth area in oncology, with PSMA PET becoming standard of care for prostate cancer and radioequivalents like PNT2003 opening therapy markets. The trend supports long-term demand, but it also attracts competitive investment from Novartis, Telix, and private buyers such as Curium.

Valuation and margin of safety

At $99.64, LNTH trades at about 23.9x trailing GAAP earnings, 18.6x forward earnings, and 17.2x free cash flow. The reported ~$7 billion Curium deal implies about $107.5 per share, roughly 8% above the current price. The margin of safety is thin in the base case and depends on the deal closing; if it fails, standalone value could be materially lower.

Source-backed data

LNTH Data Table

Every metric below includes a source and last verification date.

Metric	Value	Source	Last verified
Current price	$99.64 (close Jul 31, 2026; after-hours $98.00)	StockAnalysis.com	August 3, 2026
Market capitalization	$6.49 billion (tool-verified as $99.64 x 65.11 million shares)	StockAnalysis.com / financial_rigor.py	August 3, 2026
Shares outstanding	65.11 million, down 6.91% year over year	StockAnalysis.com	August 3, 2026
P/E ratio (TTM)	23.94x (GAAP EPS $4.16); Barchart shows 20.28x on a different EPS methodology	StockAnalysis.com / Barchart	August 3, 2026
Forward P/E	18.58x (based on consensus adjusted EPS $5.36)	StockAnalysis.com	August 3, 2026
Price / Sales, Price / Book, P/FCF	4.20x / 5.35x / 17.20x	StockAnalysis.com	August 3, 2026
Revenue (TTM)	$1.55 billion, +0.6%	StockAnalysis.com	August 3, 2026
Net income (TTM)	$279.03 million; EPS (TTM) $4.16	StockAnalysis.com	August 3, 2026
Free cash flow (TTM)	$377.11 million (operating cash flow $407.71M, capex $30.60M); FCF margin 24.39%	StockAnalysis.com	August 3, 2026
Margins	Gross 60.48%, operating 18.57%, profit 18.05%	StockAnalysis.com	August 3, 2026
ROE / ROIC	23.48% / 15.92%	StockAnalysis.com	August 3, 2026
Cash and debt	Cash $498.58 million; total debt $625.75 million; debt/equity 0.52	StockAnalysis.com	August 3, 2026
52-week range / change	$47.25 to $111.86; +38.70% over 52 weeks	StockAnalysis.com	August 3, 2026
Moving averages / RSI	50-day ~$103.53, 200-day ~$78.54, RSI 42.45	StockAnalysis.com	August 3, 2026
Q1 2026 revenue	$377.3 million (+1.2%); PYLARIFY $240.9M (-6.5%), DEFINITY $84.6M (+6.8%), Neuraceq $35.4M	Q1 2026 earnings release	August 2, 2026
Q1 2026 EPS	GAAP diluted $1.80; adjusted $1.46 (-4.6% year over year)	Q1 2026 earnings release	August 2, 2026
FY2026 guidance	Revenue $1.4B to $1.45B; adjusted EPS $5.00 to $5.25 (reaffirmed May 7, 2026)	Q1 2026 earnings release	August 2, 2026
Analyst consensus	Buy; average target $112.75 (range $98 to $129), 13 analysts	StockAnalysis.com / S&P Global	August 3, 2026
Curium acquisition report	Bloomberg reported July 28, 2026 that Curium is in advanced talks to acquire Lantheus at roughly $7 billion (about $107.5 per share implied)	Bloomberg via TheFly	August 2, 2026
LNTH-2501 FDA action	Complete Response Letter issued June 26, 2026 over third-party facility manufacturing conditions; no safety or efficacy concerns cited	Lantheus press release (GlobeNewswire)	August 2, 2026

Frequently Asked Questions

NVDA AI stock analysis TLX AI stock analysis NVS AI stock analysis Generate an AI trading strategy AI Stock Picker & Screener Stock Screener

This LNTH AI stock analysis page is an informational research tool and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Forecasts and scenario ranges are based on publicly available data as of the August 3, 2026 data cutoff, including a reported but not confirmed acquisition process, and may be materially different from future outcomes. Past performance is not indicative of future results. Investing in equities, particularly radiopharmaceutical companies with active FDA, competitive, and M&A risk, involves risk of loss. Consult a licensed financial advisor for personalized investment guidance.